Research Studies
Back to Results
A Multicenter, Open-Label, Non-Randomised First in Human Study of NG-350A in Patients with Metastatic or Advanced Epithelial Tumours (FORTITUDE)
Details
Age
Adult
Eligibility
Disease must be epithelial ( carcinoma or adenocarcinoma )
Phase
I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.
Type of Study
Treatment
Location
University of Colorado Hospital
Principal Investigator
Ross Camidge, MD, PhD
Study ID
Protocol Number: 19-1147
More information available at ClinicalTrials.gov: NCT03852511
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers